Histone H3K9 demethylase JMJD2B/KDM4B promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells by regulating H3K9me2 on RUNX2

Abstract

Background A variety of proteins including epigenetic factors are involved in the differentiation of human bone marrow mesenchymal stem cells. These cells also exhibited an epigenetic plasticity that enabled them to trans-differentiate from adipocytes to osteoblasts (and vice versa) after commitment. Further in-depth study of their epigenetic alterations may make sense. Methods Chromatin Immunoprecipitation-PCR (ChIP-PCR) was used to detect the methylation enrichment status of H3K9me2 in the Runx2 promoter, alizarin red and alkaline phosphatase (ALP) staining were used to detect osteogenic differentiation and mineralization ability, western blot and quantitative RT-PCR were used to measure the differential expression of osteogenesis-related proteins and genes. Recombinant Lentivirus mediated gain-of-function and loss-of-function study. The scale of epigenetic modification was detected by laser confocal. Results Our results showed that compared with human bone marrow mesenchymal stem cells (hBMSCs) without osteogenic differentiation treatment, hBMSCs after osteogenic differentiation significantly promoted osteogenic differentiation and mRNA expression such as JMJD2B/KDM4B, osteogenesis-related genes like Runx2 and FAM210A in hBMSCs cells, suggesting that upregulation of JMJD2B/KDM4B is involved in the promoting effect of osteogenesis. After overexpression and silencing expression of JMJD2B, we found a completely opposite and significant difference in mRNA expression of osteogenesis-related genes and staining in hBMSCs. Overexpression of JMJD2B/KDM4B significantly promoted osteogenic differentiation, suggesting that JMJD2B/KDM4B could promote osteogenesis. In addition, ChIP-PCR showed that overexpression of JMJD2B/KDM4B significantly reversed the methylation enrichment status of H3K9me2 in Runx2 promoter. Furthermore, overexpression of JMJD2B/KDM4B significantly reverses the inhibitory effect of BIX01294 on H3K9me2, suggesting that JMJD2B/KDM4B regulates the osteogenic differentiation of hBMSCs by changing the methylation status of H3K9me2 at the Runx2 promoter. Conclusions Taken together, these results suggest that JMJD2B/ KDM4B may induce the osteogenic differentiation of hBMSCs by regulating the methylation level of H3K9me2 at the Runx2 promoter.

Epigenetic control of mesenchymal stem cells orchestrates bone regeneration

“…Decreased methylation levels of the RUNX2 promoter H3K9me2 can induce osteogenic differentiation of BMSCs (100). The overexpression of KDM4A can promote osteogenic differentiation in BMSCs, knock down KDM4A, reduce the The splicing factor heterogeneous nuclear ribonucleoprotein LhnRNPL inhibits osteogenic differentiation of PDLSCs through downregulation of the H3K36me3-specific methyltransferase SETD2.…”

“…Decreased methylation levels of the RUNX2 promoter H3K9me2 can induce osteogenic differentiation of BMSCs ( 100 ). The overexpression of KDM4A can promote osteogenic differentiation in BMSCs, knock down KDM4A, reduce the promoter expression levels of RUNX2, OSX, and OCN, and increase the expression level of H3K27me3.…”

KDM4B: A promising oncology therapeutic target

“…KDM4B has the capability to enhance the expression of DLX2 and DLX5 by binding to the H3K9 site. This phenomenon promotes cellular ossification and enhances the activity of alkaline phosphatase [18][19][20][21]. This collection of mechanisms influences the process of bone damage repair.…”